

# Added Value of Reconstructive Lymphatic Surgery to Usual Care in Lymphoedema

NCT05064176

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Universitaire Ziekenhuizen KU Leuven
Enrollment	180 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Unilateral or bilateral, primary or secondary lymphoedema of the upper or lower limb
- If cancer-related lymphoedema, approval for participation in study from oncological specialist (patient participation has to be discussed during Multidisciplinary Oncological Consult); approval if:
  - estimated cancer-related survival is  $\geq 3$  years
  - oncological safety is guaranteed: for instance, time interval since radiotherapy/ chemotherapy is  $\geq 3$  months
  - Lymphoedema stage 1 to 2b
- ... and 4 more (see full listing online)

### Exclusion (6)

- Participants with history of liposuction, lymphovenous anastomosis, lymph node transfer
- Pregnant participants
- Severe obese participants: BMI  $> 35$
- Estimated cancer-related survival is  $< 3$  years and oncological safety is not guaranteed (e.g. interval since radiotherapy/ chemotherapy is  $< 3$  months)
- In case of lower limb lymphoedema: presence of chronic venous insufficiency C4, C5, C6; deep venous thrombosis; post-thrombotic syndrome
- ... and 1 more (see full listing online)

## Locations (3 total)

---

Ghent University Hospital, Ghent, Belgium  
University Hospitals of Leuven, center for lymphedema, Leuven, Belgium  
CHU-UCL Mont-Godinne, Namur, Belgium

---

<https://clinicaltrials.gov/study/NCT05064176>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).